Finch Therapeutics Group, Inc. (FNCH)
USD 12.74
(-0.08%)
USD 12.74
(-0.08%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 70.99 Million USD | -56.43% |
| 2022 | 162.93 Million USD | -27.7% |
| 2021 | 225.36 Million USD | 36.31% |
| 2020 | 165.33 Million USD | 59.64% |
| 2019 | 103.56 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 50.09 Million USD | -29.44% |
| 2024 Q2 | 45.57 Million USD | -9.02% |
| 2023 Q1 | 79.04 Million USD | -51.49% |
| 2023 FY | 70.99 Million USD | -56.43% |
| 2023 Q4 | 70.99 Million USD | 19.34% |
| 2023 Q3 | 59.49 Million USD | -11.01% |
| 2023 Q2 | 66.85 Million USD | -15.41% |
| 2022 Q2 | 228.3 Million USD | 11.57% |
| 2022 FY | 162.93 Million USD | -27.7% |
| 2022 Q1 | 204.63 Million USD | -9.2% |
| 2022 Q4 | 162.93 Million USD | -13.32% |
| 2022 Q3 | 187.96 Million USD | -17.67% |
| 2021 Q1 | 265.95 Million USD | 60.85% |
| 2021 FY | 225.36 Million USD | 36.31% |
| 2021 Q4 | 225.36 Million USD | -3.27% |
| 2021 Q3 | 232.97 Million USD | -6.93% |
| 2021 Q2 | 250.32 Million USD | -5.87% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | 165.33 Million USD | 0.0% |
| 2020 FY | 165.33 Million USD | 59.64% |
| 2019 FY | 103.56 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -23634.576% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -1137.744% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -383.137% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -127.445% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -2104.876% |
| Better Therapeutics, Inc. | 22.94 Million USD | -209.45% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -147.583% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -1804.879% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -245.585% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -236.112% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -10.174% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -2916.387% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -171.593% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -93325.71% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -483.425% |
| Molecular Templates, Inc. | 35.38 Million USD | -100.653% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -1524.048% |
| NexImmune, Inc. | 8.59 Million USD | -726.128% |
| Orgenesis Inc. | 14.55 Million USD | -387.885% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -501.568% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -56860.279% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -1149.858% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -17999.244% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 84.985% |
| Statera Biopharma, Inc. | 21.16 Million USD | -235.371% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -602.593% |
| Trevena, Inc. | 40.6 Million USD | -74.848% |
| Vaxxinity, Inc. | 44.35 Million USD | -60.073% |
| Vaccinex, Inc. | 3.63 Million USD | -1855.302% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -178932.177% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -25.233% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -12675.793% |